Reports Q4 revenue $22.8M, consensus $44.64M. “We continue to progress our flagship rare disease programs and look forward to sharing meaningful Phase 2 interim data from our cystic fibrosis and ornithine transcarbamylase deficiency programs in Q2 2025,” said Joseph Payne, President & CEO of Arcturus Therapeutics (ARCT). “Arcturus continues to make excellent progress with our STARR sa-mRNA vaccines pipeline and platform. We are very pleased to have recently received European Commission approval for KOSTAIVE and MHLW approval for Meiji Seika Pharma and ARCALIS to add commercial manufacturing sites in Japan. Our team continues to work diligently with CSL Seqirus to prepare KOSTAIVE regulatory filings for the United States and the United Kingdom.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- ARCT Upcoming Earnings Report: What to Expect?
- Arcturus Therapeutics price target raised to $48 from $41 at BTIG
- Arcturus Therapeutics: Buy Rating Affirmed on EU Approval and Promising Clinical Data for Kostaive Vaccine
- Arcturus Therapeutics and CSL’s Kostaive COVID-19 vaccine approved in Europe
- CSL, Arcturus Therapeutics announce European Commission approval for Kostaive
Questions or Comments about the article? Write to editor@tipranks.com